U.S. stocks edge higher after weekly jobless claims; Salesforce gains
DUBLIN - Investment firm Citadel Group has disclosed a 2.11% ownership position in Avadel Pharmaceuticals plc, according to a regulatory filing published Wednesday.
The disclosure, made under Irish Takeover Panel rules, reveals that Citadel holds interests in 2,064,646 shares, representing 2.11% of the pharmaceutical company. This includes 1,883,546 shares owned or controlled directly and 181,100 shares through stock-settled derivatives.
The filing also shows that Citadel maintains short positions in Avadel totaling 1,750,485 shares, or approximately 1.79% of the company. These short positions consist of 325,185 directly shorted shares and 1,425,300 shares through stock-settled derivatives.
The disclosure details numerous transactions conducted on November 18, including multiple purchases at prices ranging from $22.51 to $23.18 per share and sales between $22.90 and $25.00 per share.
The regulatory filing, known as Form 8.3, is required under Irish takeover regulations when an entity holds interests representing 1% or more of a company's securities. Such disclosures provide transparency regarding significant ownership positions during potential takeover situations.
The filing also lists extensive options positions held by Citadel, including both put and call options with various strike prices and expiration dates extending through January 2027.
Based on the press release statement, Citadel's position was reported as of November 18, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.